Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GEN1046||GEN-1046|GEN 1046|DuoBody-PD-L1x4-1BB|BNT 311||PD-L1/PD-1 antibody 67||GEN1046 is a bispecific antibody that binds to and simultaneously targets PD-L1 and TNFRSF9 (4-1BB), potentially resulting in the activation of T-lymphocytes, leading to increased anti-tumor immune response and decreased tumor growth (J. Immunotherapy Cancer, 6, 115 (2018), Abs nr: P647).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03917381||Phase Ib/II||GEN1046||GEN1046 Safety Trial in Patients With Malignant Solid Tumors||Recruiting||USA||4|